Article
Vorinostat in patients with resistant BRAFV600E mutated advanced melanoma: a proof of concept study.
Future oncology (London, England) - 1 Apr 2020
Huijberts Sanne, Wang Liqin, de Oliveira Rodrigo Leite, Rosing Hilde, Nuijen Bastiaan, Beijnen Jos, Bernards Rene, Schellens Jan, Wilgenhof Sofie
Abstract excerpt
The clinical benefit of treatment with BRAF- and MEK-inhibitors in melanoma is limited due to resistance associated with emerging secondary mutations. Preclinical and clinical studies have shown that short-term treatment with the HDAC inhibitor vorinostat can eliminate cells harboring these secondary mutations causing resistance. This proof of concept study is to determine the efficacy of sequential treatment...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.